CN107058258A - 一种逆转录酶和编码其的多核苷酸 - Google Patents
一种逆转录酶和编码其的多核苷酸 Download PDFInfo
- Publication number
- CN107058258A CN107058258A CN201611027264.1A CN201611027264A CN107058258A CN 107058258 A CN107058258 A CN 107058258A CN 201611027264 A CN201611027264 A CN 201611027264A CN 107058258 A CN107058258 A CN 107058258A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- mrna
- sequence
- reverse transcriptase
- different amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100034343 Integrase Human genes 0.000 title claims abstract description 224
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title claims abstract description 208
- 102000040430 polynucleotide Human genes 0.000 title claims description 8
- 108091033319 polynucleotide Proteins 0.000 title claims description 8
- 239000002157 polynucleotide Substances 0.000 title claims description 8
- 230000035772 mutation Effects 0.000 claims abstract description 102
- 241001529936 Murinae Species 0.000 claims abstract description 8
- 208000032839 leukemia Diseases 0.000 claims abstract description 8
- 230000003612 virological effect Effects 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 108090000790 Enzymes Proteins 0.000 claims description 154
- 102000004190 Enzymes Human genes 0.000 claims description 152
- 230000000694 effects Effects 0.000 claims description 148
- 235000001014 amino acid Nutrition 0.000 description 277
- 150000001413 amino acids Chemical group 0.000 description 276
- 229940024606 amino acid Drugs 0.000 description 273
- 108020004999 messenger RNA Proteins 0.000 description 211
- 239000000203 mixture Substances 0.000 description 209
- 108090000623 proteins and genes Proteins 0.000 description 133
- 102000004169 proteins and genes Human genes 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 92
- 239000002299 complementary DNA Substances 0.000 description 82
- 239000012634 fragment Substances 0.000 description 80
- 150000001875 compounds Chemical class 0.000 description 78
- 230000014616 translation Effects 0.000 description 65
- 238000013519 translation Methods 0.000 description 62
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 210000003705 ribosome Anatomy 0.000 description 54
- 238000000034 method Methods 0.000 description 53
- 238000012360 testing method Methods 0.000 description 53
- 102000053602 DNA Human genes 0.000 description 52
- 239000007853 buffer solution Substances 0.000 description 49
- 241000714177 Murine leukemia virus Species 0.000 description 48
- 239000000376 reactant Substances 0.000 description 44
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 42
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 42
- 230000003321 amplification Effects 0.000 description 42
- 238000003199 nucleic acid amplification method Methods 0.000 description 42
- 239000000839 emulsion Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 40
- 238000000338 in vitro Methods 0.000 description 38
- 102000039446 nucleic acids Human genes 0.000 description 37
- 108020004707 nucleic acids Proteins 0.000 description 37
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 36
- 239000013612 plasmid Substances 0.000 description 35
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 34
- 238000010839 reverse transcription Methods 0.000 description 34
- 150000007523 nucleic acids Chemical class 0.000 description 33
- 239000011049 pearl Substances 0.000 description 31
- 101710163270 Nuclease Proteins 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000013518 transcription Methods 0.000 description 27
- 230000035897 transcription Effects 0.000 description 27
- 239000000758 substrate Substances 0.000 description 26
- 230000002779 inactivation Effects 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 23
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 22
- 239000008346 aqueous phase Substances 0.000 description 22
- 239000000499 gel Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 239000011543 agarose gel Substances 0.000 description 20
- 238000003757 reverse transcription PCR Methods 0.000 description 20
- 238000005199 ultracentrifugation Methods 0.000 description 20
- 108010090804 Streptavidin Proteins 0.000 description 19
- 230000004087 circulation Effects 0.000 description 19
- 239000011535 reaction buffer Substances 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 235000020958 biotin Nutrition 0.000 description 18
- 230000002255 enzymatic effect Effects 0.000 description 18
- 229910001629 magnesium chloride Inorganic materials 0.000 description 18
- 239000003161 ribonuclease inhibitor Substances 0.000 description 18
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 17
- 101710203526 Integrase Proteins 0.000 description 17
- 101710188053 Protein D Proteins 0.000 description 17
- 101710132893 Resolvase Proteins 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 229960002685 biotin Drugs 0.000 description 17
- 239000011616 biotin Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 238000009739 binding Methods 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 238000006062 fragmentation reaction Methods 0.000 description 15
- 238000004945 emulsification Methods 0.000 description 14
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical class [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 14
- 235000011285 magnesium acetate Nutrition 0.000 description 14
- 238000010804 cDNA synthesis Methods 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 239000005720 sucrose Substances 0.000 description 13
- 102000012410 DNA Ligases Human genes 0.000 description 12
- 108010061982 DNA Ligases Proteins 0.000 description 12
- 102000006382 Ribonucleases Human genes 0.000 description 12
- 108010083644 Ribonucleases Proteins 0.000 description 12
- 108020005038 Terminator Codon Proteins 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 12
- 238000004925 denaturation Methods 0.000 description 12
- 230000036425 denaturation Effects 0.000 description 12
- 230000004907 flux Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 102000003960 Ligases Human genes 0.000 description 11
- 108090000364 Ligases Proteins 0.000 description 11
- 238000013467 fragmentation Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 108091092195 Intron Proteins 0.000 description 9
- 239000005515 coenzyme Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 229910001425 magnesium ion Inorganic materials 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108700004029 pol Genes Proteins 0.000 description 8
- 101150088264 pol gene Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- 239000007762 w/o emulsion Substances 0.000 description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 7
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 7
- 230000006287 biotinylation Effects 0.000 description 7
- 238000007413 biotinylation Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 150000002170 ethers Chemical class 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000008676 import Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 239000002159 nanocrystal Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 230000004544 DNA amplification Effects 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- IILJHHSXKFAWFD-FMEGDIDESA-N N[C@@H](CO)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O Chemical compound N[C@@H](CO)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O IILJHHSXKFAWFD-FMEGDIDESA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 102000047612 human CCN2 Human genes 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229940119265 sepp Drugs 0.000 description 3
- 230000009329 sexual behaviour Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102220473257 Crossover junction endonuclease EME1_I49V_mutation Human genes 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000034819 Mobility Limitation Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 238000013412 genome amplification Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 2
- 238000010550 living polymerization reaction Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 102200006122 rs372670098 Human genes 0.000 description 2
- 102200079129 rs864309721 Human genes 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 239000004113 Sepiolite Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 108091032917 Transfer-messenger RNA Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QOBLJVUECBDJGF-UHFFFAOYSA-N [Mg].CC(O)=O Chemical compound [Mg].CC(O)=O QOBLJVUECBDJGF-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008473 connective tissue growth Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 108010079502 exoribonuclease T Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000003257 protein preparation method Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102220253369 rs201879717 Human genes 0.000 description 1
- 102220039997 rs587778128 Human genes 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0806562.5 | 2008-04-10 | ||
| GBGB0806562.5A GB0806562D0 (en) | 2008-04-10 | 2008-04-10 | Production of nucleic acid |
| CN200980121472XA CN102057039A (zh) | 2008-04-10 | 2009-04-09 | 核酸的制备 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980121472XA Division CN102057039A (zh) | 2008-04-10 | 2009-04-09 | 核酸的制备 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107058258A true CN107058258A (zh) | 2017-08-18 |
Family
ID=39433452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611027264.1A Pending CN107058258A (zh) | 2008-04-10 | 2009-04-09 | 一种逆转录酶和编码其的多核苷酸 |
| CN200980121472XA Pending CN102057039A (zh) | 2008-04-10 | 2009-04-09 | 核酸的制备 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980121472XA Pending CN102057039A (zh) | 2008-04-10 | 2009-04-09 | 核酸的制备 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8835148B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3098308B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP5642662B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR102082768B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107058258A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009235368B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2721117A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2647272T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0806562D0 (cg-RX-API-DMAC7.html) |
| IL (2) | IL208578A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ588468A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2281035T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201503327QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009125006A2 (cg-RX-API-DMAC7.html) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110637084A (zh) * | 2017-04-26 | 2019-12-31 | 10X基因组学有限公司 | Mmlv逆转录酶变体 |
| CN111647576A (zh) * | 2020-06-24 | 2020-09-11 | 南京诺唯赞生物科技股份有限公司 | 一种热稳定性逆转录酶突变体及其应用 |
| CN111849938A (zh) * | 2020-06-05 | 2020-10-30 | 华南理工大学 | 一种突变型逆转录酶及其制备方法与应用 |
| CN112251423A (zh) * | 2020-12-08 | 2021-01-22 | 北京健为医学检验实验室有限公司 | 一种新型m-mlv逆转录酶体及其应用 |
| CN112795549A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 一种逆转录酶突变体 |
| CN112795546A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 一种具有高逆转录效率的耐高温逆转录酶突变体及其应用 |
| CN112795548A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 具有高逆转录效率的耐高温逆转录酶突变体及其应用 |
| CN112795547A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 高逆转录效率的逆转录酶突变体 |
| CN112969527A (zh) * | 2018-11-08 | 2021-06-15 | 深圳华大生命科学研究院 | 一种微流控芯片及其制备方法和dna合成方法 |
| CN114174503A (zh) * | 2019-07-26 | 2022-03-11 | 东洋纺株式会社 | 稳定性优异的突变型逆转录酶 |
| CN114214299A (zh) * | 2022-01-26 | 2022-03-22 | 苏州译酶生物科技有限公司 | 一种m-mlv逆转录酶及其制备方法 |
| CN114480331A (zh) * | 2020-11-13 | 2022-05-13 | 广州达安基因股份有限公司 | Mmlv酶组合突变体 |
| CN114480336A (zh) * | 2020-11-13 | 2022-05-13 | 广州达安基因股份有限公司 | 含有的逆转录酶突变体的核酸检测试剂盒 |
| CN114480332A (zh) * | 2020-11-13 | 2022-05-13 | 广州达安基因股份有限公司 | 耐高温m-mlv酶突变体及其应用 |
| CN114591930A (zh) * | 2022-05-10 | 2022-06-07 | 翌圣生物科技(上海)股份有限公司 | 增强型逆转录酶、编码dna、试剂盒及其在rna文库构建中的应用 |
| CN114657165A (zh) * | 2022-03-25 | 2022-06-24 | 江苏百时美生物科技有限公司 | 一种提高热稳定性和抑制剂耐受性的逆转录酶突变体及其应用 |
| CN114945663A (zh) * | 2019-11-13 | 2022-08-26 | 广州达安基因股份有限公司 | 耐高温逆转录酶突变体及其应用 |
| CN115747186A (zh) * | 2022-09-13 | 2023-03-07 | 天罗诊断科技江苏有限公司 | 一种耐热的高效率逆转录酶突变体及其应用 |
| CN116042569A (zh) * | 2023-02-01 | 2023-05-02 | 珠海宝锐生物科技有限公司 | Mmlv逆转录酶突变体及其应用 |
| CN116064460A (zh) * | 2022-08-01 | 2023-05-05 | 南京诺唯赞生物科技股份有限公司 | 一种mmlv突变体及其应用 |
| CN116622669A (zh) * | 2023-06-30 | 2023-08-22 | 翌圣生物科技(上海)股份有限公司 | 一种鼠白血病病毒逆转录酶突变体及其应用 |
| CN116694598A (zh) * | 2023-06-30 | 2023-09-05 | 翌圣生物科技(上海)股份有限公司 | 一种鼠白血病病毒逆转录酶突变体及其应用 |
| CN116814581A (zh) * | 2022-10-13 | 2023-09-29 | 苏州拜科生物科技有限公司 | 一种热稳定性反转录酶突变体基因、制备方法和应用 |
| CN117106746A (zh) * | 2022-06-01 | 2023-11-24 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
| WO2024032512A1 (zh) * | 2022-08-11 | 2024-02-15 | 菲鹏生物股份有限公司 | 一种逆转录酶、核酸分子及合成cDNA的方法 |
| CN117925558A (zh) * | 2023-12-13 | 2024-04-26 | 郑州玛特瑞斯生物科技有限公司 | 突变型逆转录酶及其应用 |
| WO2025039935A1 (zh) * | 2023-08-23 | 2025-02-27 | 翌圣生物科技(上海)股份有限公司 | Rna链特异性建库试剂盒及建库方法 |
| CN119955759A (zh) * | 2025-01-07 | 2025-05-09 | 湖南艾科瑞生物工程有限公司 | 一种mmlv逆转录酶突变体及其应用 |
| CN121249621A (zh) * | 2025-12-08 | 2026-01-02 | 翌圣生物科技(上海)股份有限公司 | 一种mmlv逆转录酶突变体及其制备方法、产品和应用 |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9771565B2 (en) * | 2000-05-26 | 2017-09-26 | Life Technologies Corporation | Thermostable reverse transcriptases and uses thereof |
| EP1554377B1 (en) | 2002-09-13 | 2012-11-07 | Life Technologies Corporation | Thermostable reverse transcriptases and uses thereof |
| US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
| GB0806562D0 (en) * | 2008-04-10 | 2008-05-14 | Fermentas Uab | Production of nucleic acid |
| US9890408B2 (en) * | 2009-10-15 | 2018-02-13 | Ibis Biosciences, Inc. | Multiple displacement amplification |
| EP2604688B1 (en) * | 2010-08-13 | 2018-01-10 | Kyoto University | Variant reverse transcriptase |
| KR101818126B1 (ko) * | 2011-02-09 | 2018-01-15 | (주)바이오니아 | 열안정성이 증가된 역전사효소 |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9745571B2 (en) * | 2013-03-07 | 2017-08-29 | Bio-Rad Laboratories, Inc. | Repetitive reverse transcription partition assay |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| WO2015075842A1 (ja) * | 2013-11-25 | 2015-05-28 | 国立大学法人京都大学 | 変異型逆転写酵素 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US9663770B2 (en) | 2014-01-22 | 2017-05-30 | Life Technologies Corporation | Reverse transcriptases for use in high temperature nucleic acid synthesis |
| CN106414704B (zh) | 2014-03-14 | 2020-11-03 | 生命技术公司 | 用于核酸扩增和检测的集成系统 |
| CN104250642A (zh) * | 2014-04-30 | 2014-12-31 | 厦门安普利生物工程有限公司 | 一种提取纯化m-mlv逆转录酶的方法 |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| CN107810415B (zh) * | 2015-05-11 | 2021-06-22 | 亿明达股份有限公司 | 用于发现和分析治疗剂的平台 |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| WO2017178986A1 (en) | 2016-04-12 | 2017-10-19 | Solis Biodyne Oü | Synthetic reverse transcriptases and uses thereof |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US9580698B1 (en) * | 2016-09-23 | 2017-02-28 | New England Biolabs, Inc. | Mutant reverse transcriptase |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US11220677B2 (en) | 2016-12-14 | 2022-01-11 | Takara Bio Inc. | Heat-resistant reverse transcriptase mutant |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| EP3610006B1 (en) | 2017-04-11 | 2021-05-19 | Roche Diagnostics GmbH | Mutant reverse transcriptase with increased thermal stability as well as products, methods and uses involving the same |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019122200A1 (en) | 2017-12-22 | 2019-06-27 | Thermo Fisher Scientific Baltics Uab | Polymerase chain reaction composition comprising amines |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| US12188014B1 (en) | 2018-07-25 | 2025-01-07 | 10X Genomics, Inc. | Compositions and methods for nucleic acid processing using blocking agents |
| US20220411783A1 (en) * | 2018-10-12 | 2022-12-29 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020132966A1 (zh) * | 2018-12-26 | 2020-07-02 | 深圳华大生命科学研究院 | 酶活性提高的逆转录酶及其应用 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| AU2020361681A1 (en) | 2019-10-10 | 2022-05-05 | 1859, Inc. | Methods and systems for microfluidic screening |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4461810A3 (en) | 2019-12-11 | 2025-04-09 | 10X Genomics, Inc. | Reverse transcriptase variants |
| EP4107273A1 (en) | 2020-02-21 | 2022-12-28 | Limagrain Europe | Prime editing technology for plant genome engineering |
| WO2021188840A1 (en) * | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US12559734B2 (en) | 2020-07-20 | 2026-02-24 | Integrated Dna Technologies, Inc. | Reverse transcriptase mutants with increased activity and thermostability |
| US12435318B2 (en) | 2020-07-20 | 2025-10-07 | Integrated Dna Technologies, Inc. | Reverse transcriptase mutants with increased activity and thermostability |
| CN114480330B (zh) * | 2020-11-13 | 2024-11-01 | 广州达安基因股份有限公司 | 多突变位点的逆转录酶突变体 |
| CN114480335B (zh) * | 2020-11-13 | 2024-06-07 | 广州达安基因股份有限公司 | 逆转录酶及逆转录检测试剂 |
| WO2022115579A1 (en) * | 2020-11-24 | 2022-06-02 | Saliogen Therapeutics, Inc. | Mammalian mobile element compositions, systems and therapeutic applications |
| CN112481234B (zh) * | 2020-12-03 | 2023-09-22 | 重庆工业职业技术学院 | 一种焦磷酸酶突变体合成核酸糖类似物及其应用 |
| CN113234858A (zh) * | 2021-05-20 | 2021-08-10 | 阿吉安(福州)基因医学检验实验室有限公司 | 一种covid-19的检测试剂盒 |
| CN113174381B (zh) * | 2021-06-08 | 2023-05-12 | 翌圣生物科技(上海)股份有限公司 | 增强型mmlv逆转录酶突变体及其应用 |
| JPWO2023112947A1 (cg-RX-API-DMAC7.html) * | 2021-12-17 | 2023-06-22 | ||
| US11639499B1 (en) | 2022-03-08 | 2023-05-02 | Watchmaker Genomics, Inc. | Reverse transcriptase variants |
| CN116004568B (zh) * | 2023-02-07 | 2025-10-17 | 北京诺派生物科技有限公司 | 一种可用于核酸检测的耐高温反转录酶及其制备方法与应用 |
| WO2024211850A1 (en) * | 2023-04-05 | 2024-10-10 | Primrose Bio, Inc. | Methods and compositions for protein engineering |
| CN116732141B (zh) * | 2023-07-10 | 2024-04-02 | 海南大学 | 一种快速检测生物dna特异性的方法 |
| CN118406670B (zh) * | 2024-05-06 | 2025-06-27 | 湖南艾科瑞生物工程有限公司 | 一种mmlv逆转录酶突变体及其应用 |
| WO2026003215A1 (fr) | 2024-06-27 | 2026-01-02 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Bases modifiées chimiquement avec un groupement clivable et méthodes de sélection d'acides nucléiques fonctionnels les comprenant |
| US20260184995A1 (en) * | 2024-12-30 | 2026-07-02 | Life Technologies Corporation | Non-ionic surfactants and methods of making and using the same |
| WO2026147782A1 (en) | 2024-12-30 | 2026-07-09 | Life Technologies Corporation | Non-ionic surfactants and methods of using the same |
| WO2026147784A1 (en) | 2024-12-30 | 2026-07-09 | Life Technologies Corporation | Non-ionic surfactants and methods of using the same |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000042199A1 (en) * | 1999-01-15 | 2000-07-20 | Molecular Biology Resources | Biologically active reverse transcriptases |
| CN1430670A (zh) * | 2000-05-26 | 2003-07-16 | 茵维特罗根公司 | 热稳定逆转录酶及其用途 |
| WO2004024749A2 (en) * | 2002-09-13 | 2004-03-25 | Invitrogen Corporation | Thermostable reverse transcriptases and uses thereof |
| US20050232934A1 (en) * | 2004-04-19 | 2005-10-20 | Ambion, Inc. | Recombinant reverse transcriptases |
| WO2007022045A2 (en) * | 2005-08-10 | 2007-02-22 | Stratagene California | Mutant reverse transcriptase and methods of use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6236563A (ja) | 1985-08-12 | 1987-02-17 | Koji Ando | 可動導体型計器 |
| US5244797B1 (en) * | 1988-01-13 | 1998-08-25 | Life Technologies Inc | Cloned genes encoding reverse transcriptase lacking rnase h activity |
| ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
| US6183967B1 (en) * | 1995-06-07 | 2001-02-06 | Nexstar Pharmaceuticals | Nucleic acid ligand inhibitors to DNA polymerases |
| US6395524B2 (en) | 1996-11-27 | 2002-05-28 | University Of Washington | Thermostable polymerases having altered fidelity and method of identifying and using same |
| CA2287542A1 (en) | 1997-04-22 | 1998-10-29 | Invitrogen Corporation | Methods for the production of aslv reverse transcriptases composed of multiple subunits |
| ATE358177T1 (de) | 1997-07-07 | 2007-04-15 | Medical Res Council | Ein in vitro sortierverfahren |
| US6136582A (en) * | 1998-01-20 | 2000-10-24 | The Trustees Of Columbia University In The City | Reverse transcriptase of moloney murine leukemia virus with RNA polymerase activity |
| JP4193079B2 (ja) | 1998-11-10 | 2008-12-10 | 東洋紡績株式会社 | 変異型逆転写酵素 |
| US7056716B2 (en) | 2000-03-15 | 2006-06-06 | Invitrogen Corporation | High fidelity reverse transcriptases and uses thereof |
| WO2001075097A2 (en) | 2000-03-31 | 2001-10-11 | Cambridge Antibody Technology Limited | Improvements to ribosome display |
| US7078208B2 (en) | 2000-05-26 | 2006-07-18 | Invitrogen Corporation | Thermostable reverse transcriptases and uses thereof |
| GB0022458D0 (en) | 2000-09-13 | 2000-11-01 | Medical Res Council | Directed evolution method |
| WO2003025132A2 (en) | 2001-09-14 | 2003-03-27 | Invitrogen Corporation | Dna polymerases and mutants thereof |
| GB0127564D0 (en) | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
| US7597700B2 (en) | 2002-04-30 | 2009-10-06 | Abbott Laboratories | Lancet removal tool |
| AU2003260786B2 (en) * | 2002-09-06 | 2008-03-13 | Isogenica Limited | In vitro peptide expression libraray |
| GB0221053D0 (en) | 2002-09-11 | 2002-10-23 | Medical Res Council | Single-molecule in vitro evolution |
| EP1691792A4 (en) * | 2003-11-24 | 2008-05-28 | Yeda Res & Dev | COMPOSITIONS AND PROCESSES FOR SORTING IN VITRO OF MOLECULE AND CELL LIBRARIES |
| EP1712617A4 (en) | 2004-01-13 | 2007-07-18 | Inst Biophysics Cn Acad Sci | RECOMBINANT REVERSE TRANSCRIPTASE OF THE MOUSE LEUKEMIA VIRUS, AND A CODING GENE AND METHOD FOR THE EXPRESSION THEREOF |
| US20080004436A1 (en) | 2004-11-15 | 2008-01-03 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Directed Evolution and Selection Using in Vitro Compartmentalization |
| JPWO2007011045A1 (ja) * | 2005-07-20 | 2009-02-05 | 株式会社クラレ | パージング剤 |
| WO2008029085A2 (en) | 2006-09-06 | 2008-03-13 | Medical Research Council | Polymerase |
| GB0806562D0 (en) * | 2008-04-10 | 2008-05-14 | Fermentas Uab | Production of nucleic acid |
-
2008
- 2008-04-10 GB GBGB0806562.5A patent/GB0806562D0/en not_active Ceased
-
2009
- 2009-04-09 EP EP16177660.4A patent/EP3098308B1/en active Active
- 2009-04-09 JP JP2011503454A patent/JP5642662B2/ja active Active
- 2009-04-09 KR KR1020197003483A patent/KR102082768B1/ko active Active
- 2009-04-09 CN CN201611027264.1A patent/CN107058258A/zh active Pending
- 2009-04-09 CN CN200980121472XA patent/CN102057039A/zh active Pending
- 2009-04-09 NZ NZ588468A patent/NZ588468A/xx not_active IP Right Cessation
- 2009-04-09 CA CA2721117A patent/CA2721117A1/en not_active Abandoned
- 2009-04-09 EP EP09730379.6A patent/EP2281035B1/en active Active
- 2009-04-09 KR KR1020107025153A patent/KR101653775B1/ko active Active
- 2009-04-09 EP EP18168458.0A patent/EP3375870B1/en active Active
- 2009-04-09 WO PCT/EP2009/054329 patent/WO2009125006A2/en not_active Ceased
- 2009-04-09 KR KR1020187003649A patent/KR101947101B1/ko active Active
- 2009-04-09 PL PL09730379T patent/PL2281035T3/pl unknown
- 2009-04-09 KR KR1020167013385A patent/KR101828902B1/ko active Active
- 2009-04-09 ES ES13167553.0T patent/ES2647272T3/es active Active
- 2009-04-09 SG SG10201503327QA patent/SG10201503327QA/en unknown
- 2009-04-09 AU AU2009235368A patent/AU2009235368B2/en not_active Ceased
- 2009-04-09 EP EP13167553.0A patent/EP2639300B1/en active Active
-
2010
- 2010-10-07 US US12/899,641 patent/US8835148B2/en active Active
- 2010-10-07 IL IL208578A patent/IL208578A/en active IP Right Grant
-
2012
- 2012-02-29 US US13/408,732 patent/US8580548B2/en active Active
-
2013
- 2013-06-19 US US13/921,989 patent/US9683251B2/en active Active
-
2014
- 2014-03-24 JP JP2014059605A patent/JP2014158473A/ja active Pending
-
2015
- 2015-11-26 JP JP2015230724A patent/JP6140792B2/ja active Active
-
2016
- 2016-06-22 IL IL246396A patent/IL246396B/en unknown
-
2017
- 2017-05-01 JP JP2017091035A patent/JP6236563B2/ja active Active
- 2017-05-02 US US15/584,565 patent/US10287614B2/en active Active
- 2017-10-30 JP JP2017208710A patent/JP6473795B2/ja active Active
-
2018
- 2018-04-20 US US15/959,090 patent/US10358670B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000042199A1 (en) * | 1999-01-15 | 2000-07-20 | Molecular Biology Resources | Biologically active reverse transcriptases |
| CN1430670A (zh) * | 2000-05-26 | 2003-07-16 | 茵维特罗根公司 | 热稳定逆转录酶及其用途 |
| WO2004024749A2 (en) * | 2002-09-13 | 2004-03-25 | Invitrogen Corporation | Thermostable reverse transcriptases and uses thereof |
| US20050232934A1 (en) * | 2004-04-19 | 2005-10-20 | Ambion, Inc. | Recombinant reverse transcriptases |
| WO2007022045A2 (en) * | 2005-08-10 | 2007-02-22 | Stratagene California | Mutant reverse transcriptase and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| DAVID LIM等: "Mutations of the RNase H C Helix of the Moloney Murine Leukemia Virus Reverse Transcriptase Reveal Defects in Polypurine Tract Recognition", 《JOURNAL OF VIROLOGY》 * |
| MARIE L. COT´等: "Murine leukemia virus reverse transcriptase: Structural comparison with HIV-1 reverse transcriptase", 《VIRUS RESEARCH》 * |
Cited By (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12577545B2 (en) | 2017-04-26 | 2026-03-17 | 10X Genomics, Inc. | MMLV reverse transcriptase variants |
| CN110637084A (zh) * | 2017-04-26 | 2019-12-31 | 10X基因组学有限公司 | Mmlv逆转录酶变体 |
| CN112969527A (zh) * | 2018-11-08 | 2021-06-15 | 深圳华大生命科学研究院 | 一种微流控芯片及其制备方法和dna合成方法 |
| CN114174503A (zh) * | 2019-07-26 | 2022-03-11 | 东洋纺株式会社 | 稳定性优异的突变型逆转录酶 |
| CN112795546A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 一种具有高逆转录效率的耐高温逆转录酶突变体及其应用 |
| CN112795547B (zh) * | 2019-11-13 | 2024-05-31 | 广州达安基因股份有限公司 | 高逆转录效率的逆转录酶突变体 |
| CN112795548A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 具有高逆转录效率的耐高温逆转录酶突变体及其应用 |
| CN112795547A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 高逆转录效率的逆转录酶突变体 |
| CN112795549B (zh) * | 2019-11-13 | 2023-11-28 | 广州达安基因股份有限公司 | 一种逆转录酶突变体 |
| CN112795549A (zh) * | 2019-11-13 | 2021-05-14 | 中山大学达安基因股份有限公司 | 一种逆转录酶突变体 |
| CN114945663A (zh) * | 2019-11-13 | 2022-08-26 | 广州达安基因股份有限公司 | 耐高温逆转录酶突变体及其应用 |
| CN112795546B (zh) * | 2019-11-13 | 2024-02-27 | 广州达安基因股份有限公司 | 一种具有高逆转录效率的耐高温逆转录酶突变体及其应用 |
| CN114945663B (zh) * | 2019-11-13 | 2024-05-31 | 广州达安基因股份有限公司 | 耐高温逆转录酶突变体及其应用 |
| CN111849938B (zh) * | 2020-06-05 | 2022-02-15 | 广州英赞生物科技有限公司 | 一种突变型逆转录酶及其制备方法与应用 |
| CN111849938A (zh) * | 2020-06-05 | 2020-10-30 | 华南理工大学 | 一种突变型逆转录酶及其制备方法与应用 |
| CN111647576A (zh) * | 2020-06-24 | 2020-09-11 | 南京诺唯赞生物科技股份有限公司 | 一种热稳定性逆转录酶突变体及其应用 |
| CN114480332A (zh) * | 2020-11-13 | 2022-05-13 | 广州达安基因股份有限公司 | 耐高温m-mlv酶突变体及其应用 |
| CN114480336A (zh) * | 2020-11-13 | 2022-05-13 | 广州达安基因股份有限公司 | 含有的逆转录酶突变体的核酸检测试剂盒 |
| CN114480331A (zh) * | 2020-11-13 | 2022-05-13 | 广州达安基因股份有限公司 | Mmlv酶组合突变体 |
| CN114480332B (zh) * | 2020-11-13 | 2023-12-05 | 广州达安基因股份有限公司 | 耐高温m-mlv酶突变体及其应用 |
| CN114480336B (zh) * | 2020-11-13 | 2023-10-20 | 广州达安基因股份有限公司 | 含有逆转录酶突变体的核酸检测试剂盒 |
| CN112251423A (zh) * | 2020-12-08 | 2021-01-22 | 北京健为医学检验实验室有限公司 | 一种新型m-mlv逆转录酶体及其应用 |
| CN114214299A (zh) * | 2022-01-26 | 2022-03-22 | 苏州译酶生物科技有限公司 | 一种m-mlv逆转录酶及其制备方法 |
| CN114657165A (zh) * | 2022-03-25 | 2022-06-24 | 江苏百时美生物科技有限公司 | 一种提高热稳定性和抑制剂耐受性的逆转录酶突变体及其应用 |
| CN114591930B (zh) * | 2022-05-10 | 2022-08-12 | 翌圣生物科技(上海)股份有限公司 | 增强型逆转录酶、编码dna、试剂盒及其在rna文库构建中的应用 |
| CN114591930A (zh) * | 2022-05-10 | 2022-06-07 | 翌圣生物科技(上海)股份有限公司 | 增强型逆转录酶、编码dna、试剂盒及其在rna文库构建中的应用 |
| CN117106746A (zh) * | 2022-06-01 | 2023-11-24 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
| CN117106746B (zh) * | 2022-06-01 | 2024-11-22 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
| CN116064460B (zh) * | 2022-08-01 | 2023-09-26 | 南京诺唯赞生物科技股份有限公司 | 一种mmlv突变体及其应用 |
| CN116064460A (zh) * | 2022-08-01 | 2023-05-05 | 南京诺唯赞生物科技股份有限公司 | 一种mmlv突变体及其应用 |
| CN117586983B (zh) * | 2022-08-11 | 2026-05-29 | 菲鹏生物股份有限公司 | 一种逆转录酶、核酸分子及合成cDNA的方法 |
| WO2024032512A1 (zh) * | 2022-08-11 | 2024-02-15 | 菲鹏生物股份有限公司 | 一种逆转录酶、核酸分子及合成cDNA的方法 |
| CN115747186B (zh) * | 2022-09-13 | 2025-05-27 | 天罗诊断科技江苏有限公司 | 一种耐热的高效率逆转录酶突变体及其应用 |
| CN115747186A (zh) * | 2022-09-13 | 2023-03-07 | 天罗诊断科技江苏有限公司 | 一种耐热的高效率逆转录酶突变体及其应用 |
| CN116814581A (zh) * | 2022-10-13 | 2023-09-29 | 苏州拜科生物科技有限公司 | 一种热稳定性反转录酶突变体基因、制备方法和应用 |
| CN116042569B (zh) * | 2023-02-01 | 2023-08-15 | 珠海宝锐生物科技有限公司 | Mmlv逆转录酶突变体及其应用 |
| CN116042569A (zh) * | 2023-02-01 | 2023-05-02 | 珠海宝锐生物科技有限公司 | Mmlv逆转录酶突变体及其应用 |
| CN116622669B (zh) * | 2023-06-30 | 2024-06-07 | 翌圣生物科技(上海)股份有限公司 | 一种鼠白血病病毒逆转录酶突变体及其应用 |
| CN116694598A (zh) * | 2023-06-30 | 2023-09-05 | 翌圣生物科技(上海)股份有限公司 | 一种鼠白血病病毒逆转录酶突变体及其应用 |
| CN116622669A (zh) * | 2023-06-30 | 2023-08-22 | 翌圣生物科技(上海)股份有限公司 | 一种鼠白血病病毒逆转录酶突变体及其应用 |
| WO2025039935A1 (zh) * | 2023-08-23 | 2025-02-27 | 翌圣生物科技(上海)股份有限公司 | Rna链特异性建库试剂盒及建库方法 |
| CN117925558A (zh) * | 2023-12-13 | 2024-04-26 | 郑州玛特瑞斯生物科技有限公司 | 突变型逆转录酶及其应用 |
| CN119955759A (zh) * | 2025-01-07 | 2025-05-09 | 湖南艾科瑞生物工程有限公司 | 一种mmlv逆转录酶突变体及其应用 |
| CN121249621A (zh) * | 2025-12-08 | 2026-01-02 | 翌圣生物科技(上海)股份有限公司 | 一种mmlv逆转录酶突变体及其制备方法、产品和应用 |
| CN121249621B (zh) * | 2025-12-08 | 2026-03-31 | 翌圣生物科技(上海)股份有限公司 | 一种mmlv逆转录酶突变体及其制备方法、产品和应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6473795B2 (ja) | 核酸の生成 | |
| CN110312800B (zh) | 处理核酸样本的方法 | |
| DK2787565T3 (en) | Transposon-end COMPOSITIONS AND METHODS TO MODIFY nucleic acids | |
| US7803550B2 (en) | Methods of producing nucleic acid molecules comprising stem loop oligonucleotides | |
| EP4461812A2 (en) | Method for preparing a next generation sequencing (ngs) library from a ribonucleic acid (rna) sample and compositions for practicing the same | |
| KR102664617B1 (ko) | 이중-가닥 콘카테머 dna를 사용하는 무세포 단백질 발현 | |
| US20190330682A1 (en) | Methods and Compositions for Improving Removal of Ribosomal RNA from Biological Samples | |
| US20220090161A1 (en) | Devices and methods for producing nucleic acids and proteins | |
| US20240344051A1 (en) | Compositions and methods for ordered and continuous complementary DNA (cDNA) synthesis across non-continuous templates | |
| JP2009178067A (ja) | 分子ディスプレイ法及びその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |